Navigation Links
A tricky tumor virus
Date:1/17/2008

Epstein-Barr virus (EBV) is a human-pathogenic virus which belongs to the herpes virus family. Almost every adult carries EBV inside. With an infestation rate of more than 90 %, EBV is one of the most successful human viruses. Its viral genome consists of double-stranded DNA, and it is one of the few known viruses which cause cancer in humans under certain circumstances. EBV-associated cancers include lymphomas (cancer of the lymph nodes), nasopharyngeal carcinoma and gastric cancer.

A protein encoded by the virus, the latent membrane protein 1 (LMP1), is required for the uncontrolled proliferation of EBV-infected cells and, thus, the formation of cancer. Arnd Kieser and his team are studying the molecular mode of action of this EBV protein. LMP1 is a membrane-bound oncoprotein that binds certain signal molecules of its host cell and thereby critically contributes to the oncogenic transformation of the cells. One of these signal proteins is the factor TRADD. TRADD stands for TNF-receptor 1-associated death domain protein. The scientists used TRADD knockout cell lines which they had established by removing the TRADD gene from the genome of human B-cells in order to demonstrate that TRADD is an essential factor for LMP1 function. They found that in the absence of TRADD, LMP1 can no longer activate a cellular communication (also called: signal transduction) pathway which is crucial for cell transformation. However, TRADD's normal function within the cell includes the induction of programmed cell death which would be fatal for the virus. In fact, the scientists made the surprising observation that TRADD can no longer induce apoptosis if it is activated by the viral protein LMP1.

How does Epstein-Barr virus manage to switch off the apoptosis function of TRADD? Kieser and his colleagues discovered that the LMP1 protein possesses a unique TRADD binding domain which dictates an unusual TRADD interaction and prevents TRADD from transmitting cell death signals. Thus, LMP1 masks the apoptotic activity of TRADD. This viral TRADD-binding domain consists of the 16 carboxyterminal amino acids of the LMP1 protein and can be transplanted to cellular receptor proteins where it shows the same effects.

Hence, Epstein-Barr virus has found a unique molecular way to extinguish an undesired property of a cellular protein in order to adapt this protein to its own needs. This finding might also be the basis for a new therapeutic approach. Arnd Kieser explains: Since the specific structure of the LMP1-TRADD interaction is most likely restricted to EBV-infected cells, it might serve as a target structure to develop specific inhibitors which interrupt the transforming signal cascade of the LMP1 oncogene.


'/>"/>

Contact: Dr. Arnd Kieser
a.kieser@helmholtz-muenchen.de
0049-897-099-535
GSF - National Research Center for Environment and Health
Source:Eurekalert

Related medicine news :

1. Findings point to molecular Achilles heel for half of breast cancer tumors
2. Transplant Drug Shrinks Tumors in Women With Rare Lung Disease
3. High-energy ultrasound sharpens view of liver tumors
4. Forever young: Differentiation blocked in tumor stem cells
5. Some Immature Brain Cells May Promote Tumors
6. Hormone may be new drug target for preventing lymphedema, tumor spread
7. Area Around Breast Tumor May Predict Cancers Spread
8. Microchip Spots Stray Tumor Cells in the Bloodstream
9. Microchip-based device can detect rare tumor cells in bloodstream
10. Even Tiny Breast Tumors May Need Aggressive Treatment
11. Even tiny breast tumors can be aggressive and may require maximum therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... “Emotions are sacred, valid, honored, encouraged. This ... positive education company Generation Mindful. To help change the mindset of parents and educators ... skills, she created the Time-In Toolkit, which launched on Kickstarter 3 weeks ago and ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... Alcovit, a ... to ramp up its marketing efforts with its product now available through Jet.com. ... to the public. The effervescent powdered drink is designed to quickly detox the body ...
(Date:8/18/2017)... ... ... “Our Mountains to Climb: A Journey of Love and Faith Through Trials”: ... faith they shared to overcome struggles in life. “Our Mountains to Climb: A Journey ... Corcoran, a retired teacher and happily married since 1999; the author’s personal experiences drive ...
(Date:8/18/2017)... ... ... “Beyond Our Imaginations: The Infinite God”: shows the importance of God in living ... of published author, Mark Lawrence, born in Michigan, the author has lived in various ... greater man of God is that I have to be more mindful of feminine ...
(Date:8/18/2017)... ... ... Mandate for Kingdom Builders”: a call to walk as citizens of the Kingdom and ... published author, John F. McGeorge, Jr. Dr. John F. McGeorge Jr., B.A., J.D., ... three decades training pastors and Christian leaders. He also met his wife, Valerija, ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... , Aug. 7, 2017  Endo International plc ... reached agreements to resolve virtually all known U.S. mesh ... discussions to resolve the known remaining U.S. claims at ... payments beginning in the fourth quarter of 2017 and ... of its second quarter 2017 results, the Company intends ...
(Date:8/4/2017)... Aug. 3, 2017  Agragen, LLC, a ... in the biopharmaceutical, nutraceutical, and aquacultural feed sectors, ... its lead drug candidates, AGR131.  This drug is ... from the blood of patients suffering from inflammatory ... bowel disease. ...
(Date:8/2/2017)... Aug. 2, 2017 Fenita J. ... as a Pinnacle Lifetime Professional in the Field ... Manager at Turing Pharmaceuticals, AG. Her skills and ... relationship building.                ... 25 years of experience as a highly successful ...
Breaking Medicine Technology: